ArticleCureus2025
Mycophenolate Mofetil as a Therapeutic Option in Refractory Immunoglobulin A Vasculitis: A Report of Two Atypical Cases.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report two rare and challenging cases of Immunoglobulin A (IgA) vasculitis with atypical clinical presentations, both of which responded favorably to treatment with corticosteroids and mycophenolate mofetil (MMF). The first case involved a patient with pulmonary-renal syndrome, a rare manifestation of IgA vasculitis. The second case presented predominantly with severe gastrointestinal manifestations and was refractory to conventional therapies, including high-dose corticosteroids, intravenous immunoglobulin (IVIG), and cryoprecipitate. In both cases, the introduction of MMF alongside corticosteroids resulted in significant clinical improvement and eventual remission. These cases underscore the potential role of MMF as an adjunctive therapy in managing severe or refractory forms of IgA vasculitis, particularly when standard treatment options prove insufficient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.